

Applied Pharmacoeconomic and Outcomes Research Forum

February 5th 2018



14 Forums and Twelve Years ...

- 1. AMCP Dossiers: Useful for Decision Making or Not? A Debate
- 2. Biologics: Drawing (or Crossing) the line of Cost vs. Benefit: A Case in Oncology
- 3. Quality Adjusted Life Years (QALY's) for Decision Making: Views from Canada & US
- 4. Using Large Databases to Inform Decision Making: Experience in 3 Healthcare Systems
- 5. Real World Data for Decision Making: Moving Beyond Clinical Trials
- 6. Pharmacoeconomics of Pharmacogenomics
- 7. Pharmacoeconomics & Pricing: Now & After Health Care Reform
- 8. What is the Business Case for Quality Improvement Initiatives?
- Specialty Pharmacy Distribution Channels & Processes: Challenges & Opportunities Today & Under Health Care Reform
- 10. Biosimilars: Challenges and Opportunities for All.
- 11. Patient Reported Outcomes: Useful for Whom?
- 12. Health Services Research: Applications & Challenges Across Healthcare Systems
- 13. New World of Biosimilars in the U.S. Current Challenges to Inform Future Directions
- 14.Drugs to treat rare and ultra-rare diseases: Beyond the price and headlines.



- Discuss commonly encountered obstacles to conducting or utilizing results of PE studies for decision making
- Explore solutions from various perspectives
 - Managed Care
 - Government
 - Pharmaceutical/Biotech Firms
 - Medical Centers
 - Academia
- Create an environment & foundation to foster larger PE/Outcomes Research Interest



Welcome "Trainees"

Michael S. Broder MD, MSHS Partnership for Health Analytic Research

Jan D. Hirsch, RPh, PhD UCSD, Skaggs School of Pharmacy & Pharmaceutical Sciences

Anthony P. Morreale, Pharm.D., MBA, BCPS PBM Services, Department of Veterans Affairs

Charles Daniels, RPh, PhD UCSD Health Department of Pharmacy

Mirta Millares, PharmD, FCSHP, FASHP Kaiser Permanente – CA Region Thanks Mirta

> Michael Pollock Reynolds Pollock & Associates

Robert Schoenhaus, PharmD Sharp HealthCare



Sponsors - Thanks!

PE Forum Sponsorship Fund & Exhibitors









Drugs for Rare & Ultra-Rare Diseases Beyond the Price and Headlines.

Price tag on gene therapy for rare form of blindness: \$850K

Nearly every \$100,000 drug approved in the last three years was for a rare disease

Biotech company's stock jumps 40% on promising drug to treat rare lung disease

U.K. Clears Glaxo's \$700,000 'Bubble Boy Disease' Gene Therapy



Flashback... & Memory Test

2013

Top 5 Sci-Fi Drugs



7 Most Famous TV Docs

2017



Dune The Spice Melange



Biosimilars of **Animal Kingdom**


2014

10 Most Important Drugs



Pharma Trivia








Cyclosporine discovery: travel policy "digging on location"





1881



Selective Culturing









Mysterious green glow on photosensitive plate across room when experimenting with encased cathode ray tube

Experimented on wife

Her hand




Wilhelm Roentgen

X-rays









No growth in areas accidently contaminated with ????



Alexander Fleming

Penicillin

EXTRA TRIVIA

Fleming born same year Petri dish invented by Julius Petri



Julius Petri



More after the Break!





Agenda

Overview current issues surrounding rare and ultra-rare diseases

Michael S. Broder, MD, MSHS President, Partnership for Health Analytic Research

Stakeholder Perspectives

Pharmaceutical Manufacturers

Denise Globe
VP and Head US Health Economics and Outcomes Research, Novartis

Health Plan/Payers


Steven G. Avey, MS, RPh Vice President Specialty Pharmacy Programs, MedImpact

Patient Advocacy Groups

Kristina Bowyer Executive Director, Patient Advocacy Ionis Pharmaceuticals, Inc.

Panel Q & A/Discussion All









Spoiled sweet clover

Hungry cow






Karl Link & Mark Stahmann

Sick cow









Harold Ridley



Intraocular Lens










40 Compounds Synthesized. All Pharmacologically Inert.

Lab Clean-Up. Found one on shelf.







It Worked!

Benzodiazepines








Forgot 3-Day Weekend

New "Bug"







Made a Broth & Drank It!



Gastritis

Helicobacter pylori Peptic Ulcer Disease



Agenda

Overview current issues surrounding rare and ultra-rare diseases

Michael S. Broder, MD, MSHS
President, Partnership for Health Analytic Research

Stakeholder Perspectives

Pharmaceutical Manufacturers

Denise Globe
VP and Head US Health Economics and Outcomes Research, Novartis

Health Plan/Payers

Steven G. Avey, MS, RPh Vice President Specialty Pharmacy Programs, MedImpact

Patient Advocacy Groups

Kristina Bowyer Executive Director, Patient Advocacy Ionis Pharmaceuticals, Inc.

Panel Q & A/Discussion All

